Skip to main content
All Posts By

laurabbook@gmail.com

How Do I Handle This Cancer Part 5 Coping With Cancer

How Do I Handle This Cancer Part 5

*October 2020* by Tess Taft, msw, licsw ©all rights reserved This is the fifth part of a seven-part series on how people cope with cancer. The first installment discussed GRIEF, DEPRESSION, and ANXIETY. The second installment included thoughts on ANGER.The third installment spoke to people who manage their feelings by WITHDRAWAL and RESIGNATION. The fourth part addressed how people…
laurabbook@gmail.com
October 16, 2020
Onc Live
FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC ResearchTreatments

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

*August 2020* The FDA has granted a priority review designation to new drug application (NDA) for tepotinib as a treatment for patient with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor a MET exon 14 (METex14) skipping mutation identified via an FDA-approved test.1 The NDA is based on data from the…
laurabbook@gmail.com
October 16, 2020
Targeted Oncology
FDA Grants Priority Review to Trilaciclib in Chemotherapy-Treated Small Cell Lung Cancer ResearchTreatments

FDA Grants Priority Review to Trilaciclib in Chemotherapy-Treated Small Cell Lung Cancer

*August 2020* The FDA has granted Priority Review to the New Drug Application (NDA) for trilaciclib (G1T28) for the treatment of patients with small cell lung cancer (SCLC) who are receiving chemotherapy, G1 Therapeutics announced in a press release. The Prescription Drug User Fee Act has an action date of…
laurabbook@gmail.com
October 16, 2020
Targeted Oncology
Homing in on Brain Mets’ Distinct Alterations Offers Hope for Precision Medicine Approach ResearchTreatments

Homing in on Brain Mets’ Distinct Alterations Offers Hope for Precision Medicine Approach

*August 2020* "Brain metastases harbor distinct clinically actionable genetic alterations compared to their primary tumors and extracranial sites." The use of targeted therapies directed at genetic alterations specific to brain metastases is emerging as a viable precision medicine approach to treating brain metastases that have developed from solid tumors rather…
laurabbook@gmail.com
October 16, 2020
Targeted Oncology
Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer ResearchTreatments

Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer

*August 2020* Research into mutations in the gene encoding the epidermal growth factor receptor (EGFR) protein has revolutionized non–small cell lung cancer (NSCLC) treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated. “It’s such a natural part of management for advanced lung cancer…
laurabbook@gmail.com
October 16, 2020